Secreted proteins and their cognate receptors are implicated in a myriad of activities that regulate cell proliferation, differentiation, and development. CREG, a cellular repressor of E1A-stimulated genes, is a secreted glycoprotein that antagonizes cellular transformation by E1A and ras. We have previously shown that CREG expression is induced very early during differentiation of pluripotent cells and, even in the absence of other inducers, CREG promotes neuronal differentiation of human teratocarcinoma NTERA-2 cells. Here we show that ectopic expression of CREG in NTERA-2 cells results in a delay of the G1/S phase transition of the cell cycle and growth inhibition. We show that CREG binds directly to the mannose-6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) dependent on CREG glycosylation. The M6P/IGF2R is a tumor suppressor that functions to control cell growth through interactions with multiple ligands. By analysing CREG activity in cells lacking M6P/IGF2R expression, we show that this receptor is required for CREG-induced growth inhibition. These studies reveal that CREG inhibits cell growth dependent on the M6P/IGF2R and suggest that interactions between CREG and a well-characterized tumor suppressor may contribute to regulation of proliferation and differentiation in multiple lineages.
Introduction
Embryonal carcinoma cells have many properties in common with pluripotent cells of the early embryo and have provided a useful in vitro model for studying aspects of embryonic development and tumorigenesis. The human teratocarcinoma cell line NTERA-2, for example, differentiates into neurons in vitro when exposed to retinoic acid (RA) and into a distinct nonneuronal cell type when induced with hexamethylene bisacetamide (HMBA) (Andrews, 1984; Fenderson et al., 1987; Simeone et al., 1990) . Treatment of NTERA-2 cells with either RA or HMBA leads to reduced cell proliferation, a decreased ability to form tumors in mice, downregulation of growth factors such as FGF4 and TGFa, and upregulation of Wnt-13 (Miller et al., 1994; Wakeman et al., 1998) . Another common downstream target of both RA and HMBA in NTERA-2 cells is the cellular repressor of E1A genes, CREG (Veal et al., 2000) . Thus, although treatment with RA and HMBA gives rise to different types of terminally differentiated cells, both inducers activate some common signaling pathways that may be important for growth inhibition and loss of tumorigenicity in NTERA-2 cells.
CREG has been shown to antagonize the ability of the adenovirus E1A oncoprotein to cooperate with oncogenic ras in the transformation of primary cells (Veal et al., 1998) . CREG mRNA is induced in NTERA-2 cells within 4 h of treatment with either RA or HMBA and ectopic expression of CREG in NTERA-2 cells enhanced the appearance of differentiation markers in response to RA treatment (Veal et al., 2000) . CREG is a secreted glycoprotein and strikingly, addition of CREG-enriched media to NTERA-2 cells promoted the appearance of neuronal differentiation markers even in the absence of an inducer such as RA (Veal et al., 2000) . A number of studies, including our own, have reported the induction of CREG mRNA during differentiation of diverse cell types such as pluripotent mouse ES cells (Veal et al., 2000) , monocytes (Piquemal et al., 2002) , and myeloid cells (Ma et al., 2002) . In addition, in a study of variations in gene expression during mouse CNS development, CREG was found in a cluster of genes whose expression is inversely correlated with cyclin D1 expression (Miki et al., 2001) . These studies suggest that CREG may be involved in an early step of differentiation, such as the reduction of proliferative potential, common to many lineages. It is therefore of interest to further define the role of CREG in regulating cell growth and identify a potential cell surface receptor for CREG.
The mannose-6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R), also known as the cationindependent M6P receptor, is a multifunctional transmembrane glycoprotein of 300 kDa (Kornfeld, 1992) . The large extracellular domain of this receptor binds to multiple classes of ligands including M6P-containing proteins, as well as proteins such as IGF-II whose binding is not glycosylation-dependent, and RA (Kornfeld, 1992; Kang et al., 1997) . The M6P/IGF2R plays an important role in regulating cell growth in development and carcinogenesis. This is supported by experiments in knockout mice, where the loss of M6P/IGF2R results in fetal overgrowth and perinatal lethality (Lau et al., 1994; Wang et al., 1994; Ludwig et al., 1996) , and by studies showing that the M6P/IGF2R gene is frequently mutated in liver, breast, lung, head and neck, and gastrointestinal cancers (De Souza et al., 1995; Hankins et al., 1996; Souza et al., 1996; Wang et al., 1997; Kong et al., 2000; Jamieson et al., 2003) . Several mechanisms likely contribute to growth suppression by M6P/IGF2R. The M6P/IGF2R binds and promotes the degradation of IGF-II, a potent mitogen that is often overproduced in tumors (Kornfeld, 1992; De Souza et al., 1997) . Furthermore, this receptor facilitates activation of latent TGF-b, a potent growth suppressor in many cell types (Dennis and Rifkin, 1991; Nykjaer et al., 1998) . In addition, the M6P/IGF2R mediates the internalization of granzyme B important for apoptosis stimulated by cytotoxic T cells (Motyka et al., 2000) , and regulates the availability and activity of lysosomal enzymes, such as cathepsins B and D. Loss of M6P/IGF2R results in hypersecretion of cathepsin B and other lysosomal proteases that may promote metastasis of malignant cells (Lorenzo et al., 2000; Xie and Kang, 2002) .
In this study, we have investigated the effects of CREG on cell proliferation. Ectopic expression of CREG results in a delay of G1/S phase transition of the cell cycle and growth inhibition in different cell types. Previous studies had suggested that CREG is modified by M6P (Journet et al., 2000) . We therefore examined the role of the M6P/IGF2R in CREG function. FarWestern analysis reveals that CREG binds directly to the M6P/IGF2R dependent on glycosylation. Furthermore, studies of CREG in cells lacking M6P/ IGF2R expression show that this receptor is required for CREG-induced growth inhibition. These studies reveal that CREG inhibits cell growth dependent on the M6P/IGF2R and suggest that interactions between CREG and M6P/IGF2R may contribute to regulation of proliferation and differentiation in multiple lineages.
Results

CREG reduces the growth rate of NTERA-2 cells
We have previously reported that ectopic expression of CREG in NTERA-2 cells enhances the appearance of differentiation markers even in the absence of an inducer such as RA (Veal et al., 2000) . To gain further insight into the biological activites of CREG we took advantage of NTERA-2 cell lines stably transfected with a vector expressing CREG from the CMV promoter: NC1 and NC2. Figure 1a shows the expression level of CREG in NTERA-2 and in the stably transfected cell lines. Densitometric analysis of the blot revealed a two fold increase in levels of CREG in NC1 and NC2 cell lines, which is well in the range of CREG induction during differentiation with RA (data not shown), giving us a relatively physiological model to study the biological activities of CREG.
In order to investigate the effect of CREG expression on cell growth, we compared the growth curves of wildtype NTERA-2 cells or cells transfected with empty vector (CMV) to CREG stably transfected cells. Cell proliferation was determined by evaluating cell number at different time points, using trypan blue exclusion assay. As shown in Figure 1b , the growth rate of the CREG-expressing cells was significantly reduced such that, after 4 days in culture, the cell number was decreased by 62% for NC1 (Pp0.01) and 60% for NC2 cells (Pp0.001) as compared to CMV or untransfected NTERA-2 cells.
Since CREG expression slowed the growth rate of NTERA-2 cells, we investigated the cell cycle distribution of these cells (Figure 2a) . Analysis of asynchronous cells revealed a different cell cycle profile for CREG-expressing cells. Typically, 32% of proliferating NTERA-2 or CMV cells were in the G1 phase of cell cycle, whereas in cells expressing CREG, NC1, and NC2, the fraction of cells in G1 increased up to 42% CREG binds M6P/IGF2R and inhibits cell growth A Di Bacco and G Gill (Pp0.001, respectively), while the number of cells in S phase decreased (Figure 2b) . Therefore, the decreased proliferation of CREG overexpressing cells may arise from a delay during G1/S phase transition.
The cyclin-dependent kinase inhibitor p27 KIP1 is one of the key regulators of cell cycle progression. p27 KIP1 has been shown to play a critical role in the growth and differentiative effects exerted by RA and other compounds in NTERA-2 cells (Baldassarre et al., 1999 (Baldassarre et al., , 2000 . Since PI flow cytometry indicated that the NC1 and NC2 cell lines were delayed in G1, we examined the expression of p27 KIP1 in these cells. Densitometric analysis of p27 KIP1 immunoblot showed a two to four fold increase in p27 KIP1 protein level in NC1 and NC2 cells compared to CMV and NTERA-2 cells (Figure 2c) , suggesting a correlation between p27 KIP1 level, CREG level, and G1 population distribution.
CREG expression inhibits anchorage-independent growth
Treatment of NTERA-2 cells with differentiating agents such as RA or HMBA leads to a loss of proliferative potential and a loss of tumorigenicity (Dmitrovsky et al., 1990; Miller et al., 1994) . Since ectopic expression of CREG also stimulates differentiation and inhibits cell growth, we decided to examine in vitro the effect of CREG on the transformed phenotype of these cells. Therefore, we assessed the capacity for anchorageindependent growth of these CREG-expressing cells by testing their ability to form colonies while suspended in soft agar. As shown in Figure 3 , the parental NTERA-2 cells form numerous large colonies after 3 weeks of growth in soft agar, indicating that, like most transformed cells, they do not have an essential requirement for matrix-derived survival and/or growth signals. In contrast, under the same conditions, NC1 and NC2 cells exhibit a significantly reduced capacity for soft agar colony formation, with a lower number of colonies formed and reduced colony size. In control experiments in which we have examined vector-transfected cells (CMV), there was no change in soft agar colony formation. Thus, ectopic expression of CREG in NTERA-2 cells attenuates anchorage-independent growth.
CREG inhibits colony formation
To further confirm the effects of CREG on cell proliferation, we transfected CREG or control CMV vector into NTERA-2 cells and we measured the ability of transfected cells to form colonies following drug selection. Transfected cells were plated at different dilutions and grown under G418 selection. After 3 weeks, colonies were stained, photographed, and counted ( Figure 4a ). As shown in Figure 4b , cells transfected with CREG show a statistically significant reduction (53%) in colony number and size, compared to CMV transfected cells (Pp0.05). Thus, in both stable and transiently transfected NTERA-2 cells, CREG suppresses cell proliferation.
CREG binds M6P/IGF2R through its M6P residues
A number of studies have suggested that the M6P/ IGF2R plays a critical role as a negative regulator of cell KIP1 in NC1 and NC2 as compared to NTERA-2 and CMV. Membranes were stripped and probed with anti-actin antibody as internal control for equal loading
CREG binds M6P/IGF2R and inhibits cell growth
A Di Bacco and G Gill growth (Dennis and Rifkin, 1991; Kang et al., 1999) . Since CREG has recently been reported to be modified by M6P (Journet et al., 2000) , we investigated the possibility that CREG protein may serve as a ligand for the M6P/IGF2R. Therefore, the ability of CREG to bind directly to the M6P/IGF2R was assessed using a FarWestern assay. Glycosylated and deglycosylated CREG, obtained following treatment with PNGaseF, were transferred to a membrane and probed with purified soluble M6P/IGF2R. Receptor binding was detected by probing with an M6P/IGF2R-specific antisera. The membrane was then stripped and reprobed with anti-CREG antisera. CREG protein displays three major glycosylated forms (Veal et al., 2000) and, as shown in Figure 5 , M6P/IGF2R bound preferentially to the glycosylated forms of CREG, while only minimal binding was observed to deglycosylated CREG. Interestingly, the M6P/IGF2R shows an apparent preference for binding to multiglycosylated forms of CREG compared to the monoglycosylated CREG. This observation is consistent with previous studies showing that the M6P/IGF2R binds cooperatively to ligands with more than one M6P (MacDonald, 1991) . Thus, binding of CREG to the M6P/IGF2R is direct and dependent on the M6P moieties of CREG.
M6P/IGF2R is required for CREG-mediated growth inhibition
In order to determine if binding of glycosylated CREG to the M6P/IGF2R contributed to or antagonized CREG-mediated growth suppression, we compared CREG activity in cells lacking or expressing the receptor. MS cells are M6P/IGF2R-deficient mouse L cells, while MS9-II cells have been stably transfected to express the human M6P/IGF2R (Nolan et al., 1990) . Both cell lines were transfected with plasmids expressing CREG or CMV and plated for clonogenic growth assay. After 3 weeks, colonies were stained and counted. As shown in Figure 6a , there was a statistically significant reduction in colony number (53%) in MS9-II cells transfected with CREG compared to CMV transfected cells (Pp0.05), similar to what we observed in NTERA-2 cells (Figure 4 ). In contrast, in MS cells lacking M6P/ IGF2R expression, the number of colonies obtained following transfection with CREG or CMV was comparable and did not yield a statistically significant difference (PX0.6) ( Figure 6b ). The lack of growth inhibition upon CREG transfection in MS cells lacking M6P/IGF2R expression is not due to reduced expression of CREG in these cells, as similar levels were observed following transient transfection of CREG in both MS and MS9-II cell lines (data not shown). Thus, the growth suppressive activity of CREG is not confined to a particular cell type and it requires the expression of M6P/IGF2R.
M6P/IGF2R regulates endogenous CREG localization
Since the M6P/IGF2R is well characterized as a trafficking receptor whose activities include intracellular transport to lysosomes, localization of proteins at the cell surface, and internalization of extracellular ligands (Kang et al., 1998; Blanchard et al., 1999; Godar et al., 1999; Jadot et al., 1999) , we investigated the possibility that the M6P/IGF2R might be important for CREG localization. Previous immunofluorescence studies of transiently transfected CREG showed predominant staining of overexpressed CREG in the ER and Golgi (Veal et al., 2000) . As shown in Figure 7a , immunostaining of endogenous CREG in HeLa cells (which express M6P/IGF2R) revealed that CREG is present in circular clusters near the cell periphery. In order to confirm that the punctate cytoplasmic staining pattern observed corresponds to endogenous CREG, we have used siRNA to inhibit CREG expression. As shown in Figure 7a , in cells cotransfected with GFP and the CREG siRNA vector, the punctate cytoplasmic CREG immunostaining is specifically lost. We have therefore carried out immunofluorescence studies with the CREG antisera in MS and MS9-II cells to determine the effect of the M6P/IGF2R on endogenous CREG subcellular distribution. As shown in Figure 7b , c, in the M6P/ IGF2R-expressing MS9-II cells, CREG is present in circular clusters near the cell periphery similar to the pattern observed in HeLa cells. In contrast, in the M6P/ IGF2R-negative MS cells these clusters are dramatically reduced, although the level of endogenous CREG in both cell lines is similar as shown by immunoblotting (Figure 7d ). Although the M6P/IGF2R is involved in lysosomal enzyme trafficking, we did not observe colocalization between CREG and the lysosomal protein LAMP-1 (data not shown). Thus, the M6P/ IGF2R may be required for CREG-mediated growth suppression due to an important role in CREG trafficking.
Discussion
Differentiation of human embryonal carcinoma NTERA-2 cells induced by RA or HMBA is characterized by altered patterns of gene expression, reduced proliferation potential, and loss of tumorigenicity (Miller et al., 1994) . We have now extended our previous work (Veal et al., 2000) to show that increased expression of CREG, which is induced in NTERA-2 cells following treatment with both RA and HMBA, leads to a reduction in cell proliferation (Figures 1 and  4 ) and attenuates anchorage-independent growth (Figure 3 ), a feature of many transformed cells in vitro.
These findings are consistent with our previous studies showing that CREG antagonizes the ability of the adenovirus E1A oncoprotein to cooperate with onco- Figure 5 CREG binds directly to the M6P/IGF2R. CREG conditioned media untreated (À) or treated ( þ ) with the deglycosylase PNGaseF was separated by gel electrophoresis and transferred onto nitrocellulose. The membrane was probed with purified soluble M6P/IGF2R followed by detection with anti-M6P/IGF2R antibody. Subsequently, the membrane was stripped and reprobed with anti-CREG antibody. M6P/IGF2R binds preferentially to the glycosylated forms of CREG with an apparent increased affinity for multiglycosylated CREG CREG binds M6P/IGF2R and inhibits cell growth A Di Bacco and G Gill genic ras in the transformation of primary cells (Veal et al., 1998) . Furthermore, we have shown that CREG binds directly to the M6P/IGF2R (Figure 5 ), and that cells lacking this receptor are insensitive to CREGmediated growth suppression ( Figure 6 ). The finding that CREG cooperates with the M6P/IGF2R to suppress cell growth is of particular significance since this receptor has well characterized growth and tumor suppressive properties. Our analysis of NTERA-2 cells stably expressing CREG has shown a significant reduction in cell growth compared to control CMV or untransfected NTERA-2 cells (Figure 1b) . Cell cycle profile analysis demonstrated that an increased fraction of CREG-expressing cells were found in G1 phase compared to control cells (Figure 2a, b) . It has been suggested that the rate of G1 passage and alterations in G1 duration can affect the ability of cells to respond to antimitogenic signals that withdraw cells from the cell cycle (Casaccia-Bonnefil et al., 1997; Mitsuhashi et al., 2001 ). Failure to coordinate growth arrest and differentiation may result in a failure to form normal tissues because cells either continue to proliferate (Kipreos et al., 1996) or undergo apoptosis (Boudreau et al., 1996) . Growth arrest of NTERA-2 cells induced by both RA and HMBA is preceeded by early accumulation of p27 KIP1 but not of other cdk inhibitors. Antisense experiments have shown that loss of p27 KIP1 accumulation results in failure to block cell growth and to progress along the differentiative pathway properly. In particular it was observed that NTERA-2 p27AS cells continue to proliferate in response to RA (Baldassarre et al., 2000) , while inhibition of HMBA-induced p27 KIP1 upregulation in NTERA-2 p27AS cells resulted in massive cell death (Baldassarre et al., 1999) . Interestingly, we found that expression of the cdk inhibitor p27 KIP1 was increased in CREG-expressing cells (Figure 2c ). Since CREG is induced by both RA and HMBA treatments in NTERA-2 cells, it is possible that CREG induction is one of the mechanisms through which these agents achieve p27 KIP1 upregulation and growth inhibition. The M6P/IGF2R is a multifunctional transmembrane glycoprotein that suppresses cell growth. The M6P/ IGF2R is essential for normal fetal development (Lau et al., 1994; Wang et al., 1994; Ludwig et al., 1996) and loss of function mutations or deletions are associated with human tumors in a variety of tissues including liver, breast, lung, head and neck, and gastrointestinal cancers (De Souza et al., 1995; Hankins et al., 1996; Souza et al., 1996; Wang et al., 1997; Kong et al., 2000; Jamieson et al., 2003) . The M6P/IGF2R has been suggested to function as a growth and tumor suppressor by regulating the localization, activity, and degradation of many ligands including both M6P-containing proteins and nonglycosylated proteins (Kornfeld, 1992; Kang et al., 1997) . It is interesting to note that in addition to the many signaling proteins that are ligands for the M6P/IGF2R, RA has also been suggested to bind directly to the M6P/IGF2R and this interaction may contribute to the growth suppressive effects of retinoids (Kang et al., 1998) . We have shown that CREG binds directly to the M6P/IGF2R and that this binding is dependent on glycosylation of CREG. These findings are consistent with previous studies suggesting that CREG is modified by M6P (Journet et al., 2000) . Although M6P is an important signal for lysosomal sorting, many nonlysosomal proteins are also modified by M6P including proliferin (Lee and Nathans, 1988), transforming growth factor-b precursor (Purchio et al., 1988) , epidermal growth factor receptor (Todderud and Carpenter, 1988) , leukemia inhibitory factor, and macrophage-colony-stimulating factor (Blanchard et al., 1999) . Moreover, immunofluorescence studies on CREG subcellular localization did not reveal the presence of CREG in lysosomes (Figure 7 and data not shown).
Since one of the best-characterized functions of the M6P/IGF2R is to mediate endocytosis and degradation of extracellular M6P-containing proteins and IGF-II, an important question raised by the direct interaction of CREG with M6P/IGF2R is whether this is the degradative pathway for CREG. Our results comparing CREG-mediated growth inhibition in cells lacking or expressing the M6P/IGF2R indicate that this is not the case. If the M6P/IGF2R mediated CREG degradation, we might have expected to see an increased effect of CREG on cells lacking the receptor. This was not observed. Transfection of CREG in M6P/IGF2R-expressing cells results in a significant reduction of colony number, whereas transfection of CREG in M6P/ IGF2R-deficient cells has no effect on colony formation, despite the fact that both cell lines express similar level of CREG protein ( Figure 6 and data not shown). These findings show that rather than antagonizing CREG, the M6P/IGF2R is required for CREG-mediated growth suppression.
We are currently considering two models for how the M6P/IGF2R and CREG cooperate to suppress cell growth. First, binding to the M6P/IGF2R could be required for proper localization of CREG. The receptor could concentrate CREG at the cell surface and promote an efficient interaction of CREG with another cell surface protein, as shown for uPAR (Nykjaer et al., 1998) , or mediate internalization of CREG to localize it to its site of action, as shown for CD26 (Ikushima et al., 2000) . The immunofluorescence data presented here In the second model, the binding of CREG to M6P/ IGF2R could alter receptor trafficking as shown for RA (Kang et al., 1998) , and/or the binding to other ligands as shown for beta-galactosidase (MacDonald et al., 1988; Waheed et al., 1988; Kiess et al., 1990) . Ligand occupancy of the M6P-binding domain has been suggested to influence the conformation of the M6P/ IGF2R resulting in a more optimal display of the internalization signals in the cytoplasmic domain (MacDonald, 1991) . Our preliminary data are consistent with a model whereby CREG may alter the binding or trafficking of some of the M6P/IGF2R ligands. We have observed a reduction in the response to IGF-II-induced proliferation in NTERA-2 cells stably expressing CREG (NC2) compared to control CMV cells, whereas no effects have been observed on the levels of secretion or activation of the latent TGF-b in these cell lines (unpublished data ADB and GG). Thus, the two models described here may not be mutually exclusive, and the cooperation between M6P/IGF2R and CREG to suppress cell growth could be complex: CREG binding to the M6P/IGF2R may be required for CREG localization and/or activation, but CREG may also influence receptor interactions with other ligands.
CREG protein is extraordinarily well conserved throughout evolution from plants to mammals, but CREG lacks any recognizable protein motifs or domains. Recently, a novel member of what now appears to be the 'CREG family', CREG2, has been identified (Kunita et al., 2002) . Human and mouse CREG2 show approximately 35% amino-acid identity to human, mouse, and drosophila CREG proteins. Similar to CREG, CREG2 does not contain any recognizable sequence motifs except for an N-terminal signal sequence and sites for N-glycosylation. In contrast to CREG, which is ubiquitously expressed in adult tissues, CREG2 expression is restricted to the brain. It will be interesting to see if CREG2, like CREG, binds M6P/IGF2R and if it plays any role in the control of cell growth and/or differentiation in the nervous system.
In conclusion, this study has shown that the secreted glycoprotein CREG inhibits cell growth in different cell types and that binding to the M6P/IGF2R is required for CREG-mediated growth suppression. Although the details of the mechanism of by which CREG inhibits cell growth remain to be elucidated, it is intriguing that CREG is extremely conserved throughout evolution. Therefore, additional studies on CREG function and mechanism of action may provide new insights into an ancient mechanism of cell growth control.
Materials and methods
Cell culture
NTERA-2, CMV, NC1, and NC2 cells were grown in Dulbecco's modified Eagle's medium (DMEM) (Gibco) containing 10% fetal bovine serum (FBS), 50 U/ml penicillin, 50 U/ml streptomycin and 2 mm of l-glutamine. In addition, CMV, NC1, and NC2 cells were grown in presence of 600 mg/ ml of G418 (Cellgro). MS and MS9-II cells (Nolan et al., 1990) were grown in DMEM supplemented with 5% dialyzed FBS, 0.1 g/l sodium pyruvate, 2.2 g/l Sodium bicarbonate, 100 U/ml streptomicin, 100 U/ml penicillin, 1.2 mm l-glutamine, 3.2 mm of methotrexate and 400 mg/ml of G418.
Plasmids and transfections
NTERA-2 cells were transfected with either CREG plasmid or empty vector (CMV) (Veal et al., 1998) using GeneJammer (Stratagene). MS and MS9-II cells were cotransfected with either CREG or CMV plasmids in combination with pBABE (Morgenstern and Land, 1990) carrying puromycin resistance, using Lipofectamine-2000 (Invitrogen) .
Cell growth assay
Cells were plated in six-well plates at an initial density of 25 000 cells/well. Manual cell counts were performed using 0.4% trypan blue dye exclusion (Gibco BRL) at different time points. Cell counts were averaged and standard error was determined from three independent experiments.
Flow cytometry using propidium iodide
Cells in exponential growth phase were trypsinized, pelleted and washed once with PBS. Cells were then fixed overnight at À201C with 70% cold ethanol. After a wash in PBS, pellets were resuspended in 100 ml of staining buffer (3.4 mm trisodium citrate; 9.65 mm NaCl; 0.03% NP40) containing 200 mg/ml RNAse A and incubated at 371C for 30 min. Propidium iodide was then added to the samples at final concentration 20 mg/ml and incubate at room temperature (RT) for 30 min. Data were collected and analysed by FACS using CellQuest. Mean and standard errors of at least three independent experiments are shown.
Immunoblots
Cells in exponential growth were collected in RIPA buffer (Tris-HCl 50 mm, pH 7.4; NP-40 1%; Na-deoxycholate 0.25%; NaCl 150 mm; EDTA 1 mm) supplemented with protease inhibitors (1 mm PMSF; 1 mm Na 3 VO 4 ; 1 mm NaF; 1 mg/ml Antipain; 1 mg/ml Aprotinin; 1 mg/ml Chymostatin; 1 mg/ml Pepstatin and 1 mg/ml Leupeptin). Samples were electrophoresed on 12% SDS-polyacrylamide gels then transferred onto nitrocellulose membranes (Schleicher & Schuell) . Western blots were incubated overnight at 41C with one of the following antisera: pAb CREG (Veal et al., 1998) , mAb p27 (F-8) (Santa Cruz), mAb actin (Sigma). Bound antibody was detected using either a horseradish peroxidase-linked sheep anti-mouse or donkey anti-rabbit secondary antibody and the ECL detection system (Perkin-Elmer Life Sciences). Densitometric analysis has been performed on all the immunoblots.
Production of CREG-conditioned media
293T cells were transfected with CREG plasmid using Lipofectamine (Invitrogen). At 5 h after transfection, the media was replaced with complete DMEM containing 10% FBS, 50 U/ml penicillin, 50 U/ml streptomycin and 2 mm of lglutamine. After incubation at 371C overnight, DMEM was replaced by serum-free DMEM and cells were cultured on additional 2 days. The conditioned medium was harvested, centrifuged, filtered and 10 mm HEPES was added.
FarWestern blotting analysis
FarWestern analysis was carried out as described in Ikushima et al. (2000) with some variations. Briefly, conditioned media was TCA precipitated and part of the pellet was deglycosylated using peptide-N-glycosidase F (PNGaseF) as described in the manufacturer's protocol. Both enzyme-treated and native CREG conditioned media were electrophoresed on 12% gel, and transfered onto a nitrocellulose membrane (Schleicher & Schuell) . After blocking with 3% BSA/PBS for 1 h at RT, membrane was incubated overnight at 41C with 0.5 mg/ml purified soluble M6P/IGF2R (kindly provided by Dr RG MacDonald). Following three washes with PBS, the membrane was reincubated overnight at 41C with anti-M6P/IGF2R antibody 1 : 1000 (kindly provided by Dr P Lobel). After three washes in PBS, membrane was incubated with horseradish peroxidase-conjugated anti-rabbit antibody 1 : 1000 (Promega) for 1 h at RT. Signal was then detected using ECL (PerkinElmer Life Science). Membrane was subsequently stripped and reprobed overnight at 41C with rabbit anti-CREG antibody 1 : 5000, and with horseradish peroxidase-conjugated antirabbit antibody 1 : 1000 (Promega) for 1 h at RT.
Clonogenic assay
NTERA-2 cells were transfected with CREG or CMV vector using Gene Jammer (Stratagene), while MS and MS9-II cells were transfected with CREG or CMV vector, in combination with pBABE using Lipofectamine 2000 (Invitrogen). At 5 h after transfection, the media was replaced with complete DMEM and after 20 h cells were trypsinized and replated, at different dilutions, in triplicate in 10-cm tissue culture dishes. Twentyfour hours later, cells were placed under drug selection with either 600 mg/ml of G418 (NTERA-2 cells) or 5 mg/ml of puromycin . Fresh selection media was replaced every 2 days. These concentrations of G418 and puromycin were sufficient to kill all the nontransfected control cells within 7 and 5 days, respectively. After 21 days, colonies were fixed and stained with 0.1% crystal violet (Majik Stain). Mean percentage and standard error was determined from three independent experiments.
Colony formation in soft agar
Anchorage-independent growth was determined by assaying colony formation in soft agar as described by Koleske et al. (1995) . Briefly, 1 Â 10 3 to 5 Â 10 3 cells were suspended in DMEM containing 10% FBS and 0.3% of low melting agarose (Gibco BRL). Cells were then plated in a 35 mm dish over a 1.5 ml layer of solidified DMEM containing 10% FBS and 0.6% agarose. Medium was replaced every 2-3 days by adding 200 ml of complete DMEM with or without G418 to cell suspension. Colonies were then photographed at Â 20 magnification after 3 weeks.
Immunofluorescence staining MS and MS9-II cells were plated on coverslips and fixed with 4% paraformaldehyde for 10 min at RT. After three washes, with PBS, cells were permeabilized with 0.5% Triton X-100 for 5 min at RT. Following washes with PBS, cells were incubated with normal donkey serum 1 : 10 in PBS/0.01% Triton X-100 for 30 min at RT. Without washing, coverslips were then incubated for 1 h at RT with 1 : 50 dilution of anti-CREG polyclonal antibody in PBS/0.01% Triton X-100. After three washes cells were incubated in 1 : 100 dilution of Texas Redconjugated goat anti-rabbit antibody (Amersham) in PBS/ 0.01% Triton X-100 containing 1 : 10 dilution normal donkey serum for 1 h at RT in the dark. Coverslips were then washed three times in PBS, stained with Hoechst 1 : 20 for 5 min at RT, washed again and mounted in Vectashield. Coverslips were analysed by fluorescence microscopy (Leica) using objective Â 60.
Construction and transfection of CREG siRNA plasmids
The construction of CREG siRNA plasmids were carried out as previously described in Sui et al. (2002) . The sequences for CREG siRNA are the following: oligo1 5 0 -GGTCCTGGAC-TACTTTGGTGGA-3 0 (forward) and 5 0 -AGCTTCCACCA-AAGTAGTCCAGGACC-3 0 (reverse); oligo 2 5 0 -AGCTTC-CACCAAAGTAGTCCAGGACCCTTTTTG-3 0 (forward) and 5 0 -AATTCAAAAAGGGTCCTGGACTACTTTGGTG-GA-3 0 (reverse). The individual repeat motifs were then subcloned, in two separate steps, into the parent plasmid Bluesript/U6 (gift of Dr G Sui). CREG siRNAs plasmid (3 mg) and separate plasmid encoding GFP (ratio 1 : 20) were cotransfected in Hela cells, grown on coverslips, by using calcium phosphate method and immunostained with anti-CREG antibody 2-3 days after transfection.
Statistical methods
Student's two-tailed t-test for independent samples was used. Mean and standard errors of at least three independent experiments are given unless indicated otherwise. A P-value p0.05 was considered to be statistically significant.
